In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on AC Immune SA (ACIU), with a price target of $8. The company’s shares closed on Friday at $3.98, close to its 52-week low of $3.25.
Fein wrote:
“We lowered our PT from $18 to $8 given the discontinuation of crenezumab. Our new 12-month price target of $8/share is based on an equally weighted composite of (a) $9.32/share, as a 35x multiple of taxed and diluted FY27 GAAP EPS of $1.14 discounted back to and (b) an NPV of $6.20/share (discount rate 11.0%, growth rate 2.5%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biotechnology company.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.2% and a 44.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
AC Immune SA has an analyst consensus of Moderate Buy, with a price target consensus of $10.
See today’s analyst top recommended stocks >>
Based on AC Immune SA’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $13.74 million. In comparison, last year the company had a net profit of $4.22 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
